{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T14:53:05Z","timestamp":1794840785023,"version":"4.9.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Fibrodysplasia ossificans progressiva (FOP) is an autosomal dominant ultra-rare disease characterized by progressive episodic multi-focal heterotopic ossification of skeletal muscle, ligaments, tendons, and fascia. Comprehensive characterization and understanding of the natural disease history of FOP, including mortality, comorbidities, and medication use, is currently limited.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>This systematic review, which we believe is the first of its kind, aims to synthesize current knowledge on the morbidity, mortality, and medication use associated with FOP.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A systematic literature review (SLR) was conducted utilizing various databases including PubMed, Embase, the Cochrane Central Register of Controlled Trials, the Trip database, and National Institute for Health and Care Excellence documents. The search was limited to studies involving humans, but was not restricted based on language. The studies used reported at least one of the following outcomes: mortality, comorbidity, and medication use; any clinical trials that were solely designed to evaluate a symptomatic treatment for FOP, such as flare-ups and pain, were excluded. Two independent reviewers reviewed and selected the included studies of the review, and extraction was done by one reviewer with cross-check performed by the other person. The Joanna Briggs Institute Critical Appraisal Checklist, specifically designed for studies reporting prevalence data, was used to assess the quality of studies. The SLR was registered on Prospero (CRD42022366914).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In total, 32 publications were selected for review. These studies included a wide range of participants age (0.1\u201378\u00a0years), study duration (1\u00a0day\u201333\u00a0years), and sample size (3\u2013299 patients). Ten studies reported information on mortality, 26 studies reported on comorbidities, and 12 reported information on medication use. The three organ systems most affected by the conditions studied were, in order of severity, the cardiovascular (40\u201370%), skeletal (50\u201365%), and respiratory (20\u201342%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Although FOP is an ultra-rare disease, the available literature demonstrates that it is associated with excess morbidity and mortality. Our review synthesized all available published estimates of epidemiologic landscape of FOP and demonstrates the need for future work to better understand this rare disease.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13023-025-03763-8","type":"journal-article","created":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T09:36:20Z","timestamp":1748684180000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Understanding the clinical morbidity and mortality of fibrodysplasia ossificans progressiva: a systematic literature review"],"prefix":"10.1186","volume":"20","author":[{"given":"Hind","family":"Harrak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"Souttou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah J.","family":"O\u2019Meara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Knox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,31]]},"reference":[{"key":"3763_CR1","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1385\/BMM:3:3-4:183","volume":"3","author":"FS Kaplan","year":"2005","unstructured":"Kaplan FS, Glaser DL, Shore EM, Deirmengian GK, Gupta R, Delai P, et al. The phenotype of fibrodysplasia ossificans progressiva. Clin Rev Bone Miner Metab. 2005;3:183\u20138.","journal-title":"Clin Rev Bone Miner Metab"},{"issue":"5","key":"3763_CR2","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1159\/000365770","volume":"5","author":"I H\u00fcning","year":"2014","unstructured":"H\u00fcning I, Gillessen-Kaesbach G. Fibrodysplasia ossificans progressiva: clinical course, genetic mutations and genotype-phenotype correlation. Mol Syndromol. 2014;5(5):201\u201311.","journal-title":"Mol Syndromol"},{"issue":"5","key":"3763_CR3","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/ng1783","volume":"38","author":"EM Shore","year":"2006","unstructured":"Shore EM, Xu M, Feldman GJ, Fenstermacher DA, Cho T-J, Choi IH, et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet. 2006;38(5):525\u20137.","journal-title":"Nat Genet"},{"key":"3763_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/00003086-199808000-00002","volume":"346","author":"LF Peltier","year":"1998","unstructured":"Peltier LF. A case of extraordinary exostoses on the back of a boy 1740. John Freke (1688\u20131756). Clin Orthop Relat Res. 1998;346:5\u20136.","journal-title":"Clin Orthop Relat Res"},{"issue":"4","key":"3763_CR5","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.bone.2012.07.002","volume":"51","author":"A Morales-Piga","year":"2012","unstructured":"Morales-Piga A, Bachiller-Corral J, Trujillo-Tiebas MJ, Villaverde-Hueso A, Gamir-Gamir ML, Alonso-Ferreira V, et al. Fibrodysplasia ossificans progressiva in Spain: epidemiological, clinical, and genetic aspects. Bone. 2012;51(4):748\u201355.","journal-title":"Bone"},{"issue":"1","key":"3763_CR6","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1186\/s13023-021-01983-2","volume":"16","author":"RJ Pignolo","year":"2021","unstructured":"Pignolo RJ, Hsiao EC, Baujat G, Lapidus D, Sherman A, Kaplan FS. Prevalence of fibrodysplasia ossificans progressiva (FOP) in the United States: estimate from three treatment centers and a patient organization. Orphanet J Rare Dis. 2021;16(1):350.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3763_CR7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13023-017-0674-5","volume":"12","author":"G Baujat","year":"2017","unstructured":"Baujat G, Choquet R, Bou\u00e9e S, Jeanbat V, Courouve L, Ruel A, et al. Prevalence of fibrodysplasia ossificans progressiva (FOP) in France: an estimate based on a record linkage of two national databases. Orphanet J Rare Dis. 2017;12(1):123.","journal-title":"Orphanet J Rare Dis"},{"key":"3763_CR8","unstructured":"Food and Drug Administration. Rare diseases: considerations for the development of drugs and biological products 2023. https:\/\/www.fda.gov\/media\/119757\/download."},{"key":"3763_CR9","unstructured":"Cochrane Central Register of Controlled Trials (CENTRAL). https:\/\/www.cochranelibrary.com\/central\/about-central."},{"key":"3763_CR10","unstructured":"Trip Database. https:\/\/www.tripdatabase.com\/."},{"key":"3763_CR11","unstructured":"National Institute for Health and Care Excellence. https:\/\/www.nice.org.uk\/."},{"issue":"3","key":"3763_CR12","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/XEB.0000000000000054","volume":"13","author":"Z Munn","year":"2015","unstructured":"Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. Int J Evid Based Healthc. 2015;13(3):147\u201353.","journal-title":"Int J Evid Based Healthc"},{"issue":"1","key":"3763_CR13","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s12891-020-3170-3","volume":"21","author":"D She","year":"2020","unstructured":"She D, Li R, Fang P, Zong G, Xue Y, Zhang K. Serum osteocalcin level is associated with the mortality in Chinese patients with fibrodysplasia ossificans progressiva aged \u226418 years at diagnosis. BMC Musculoskelet Disord. 2020;21(1):152.","journal-title":"BMC Musculoskelet Disord"},{"key":"3763_CR14","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.bone.2017.10.009","volume":"109","author":"KL Wentworth","year":"2018","unstructured":"Wentworth KL, Bigay K, Chan TV, Ho JP, Morales BM, Connor J, et al. Clinical-pathological correlations in three patients with fibrodysplasia ossificans progressiva. Bone. 2018;109:104\u201310.","journal-title":"Bone"},{"issue":"1","key":"3763_CR15","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1302\/0301-620X.64B1.7068725","volume":"64","author":"JM Connor","year":"1982","unstructured":"Connor JM, Evans DA. Fibrodysplasia ossificans progressiva. The clinical features and natural history of 34 patients. J Bone Jt Surg Br. 1982;64(1):76\u201383.","journal-title":"J Bone Joint Surg Br."},{"issue":"3","key":"3763_CR16","doi-asserted-by":"publisher","first-page":"686","DOI":"10.2106\/JBJS.I.00705","volume":"92","author":"FS Kaplan","year":"2010","unstructured":"Kaplan FS, Zasloff MA, Kitterman JA, Shore EM, Hong CC, Rocke DM. Early mortality and cardiorespiratory failure in patients with fibrodysplasia ossificans progressiva. J Bone Jt Surg Am. 2010;92(3):686\u201391.","journal-title":"J Bone Joint Surg Am"},{"issue":"4","key":"3763_CR17","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/S0194-59989670253-X","volume":"114","author":"HB Janoff","year":"1996","unstructured":"Janoff HB, Zasloff MA, Kaplan FS. Submandibular swelling in patients with fibrodysplasia ossificans progressiva. Otolaryngol Head Neck Surg. 1996;114(4):599\u2013604.","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"336","key":"3763_CR18","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/00003086-199703000-00033","volume":"336","author":"JM Moriatis","year":"1997","unstructured":"Moriatis JM, Gannon FH, Shore EM, Bilker W, Zasloff MA, Kaplan FS. Limb swelling in patients who have fibrodysplasia ossificans progressiva. Clin Orthop Relat Res. 1997;336(336):247\u201353.","journal-title":"Clin Orthop Relat Res"},{"issue":"12","key":"3763_CR19","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1016\/j.gim.2022.08.013","volume":"24","author":"RJ Pignolo","year":"2022","unstructured":"Pignolo RJ, Baujat G, Brown MA, De Cunto C, Hsiao EC, Keen R, et al. The natural history of fibrodysplasia ossificans progressiva: a prospective, global 36-month study. Genet Med. 2022;24(12):2422\u201333.","journal-title":"Genet Med"},{"key":"3763_CR20","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1097\/00003086-199801000-00016","volume":"346","author":"DL Glaser","year":"1998","unstructured":"Glaser DL, Rocke DM, Kaplan FS. Catastrophic falls in patients who have fibrodysplasia ossificans progressiva. Clin Orthop Relat Res. 1998;346:110\u20136.","journal-title":"Clin Orthop Relat Res"},{"issue":"1","key":"3763_CR21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1044\/1059-0889(1999\/011)","volume":"8","author":"CE Levy","year":"1999","unstructured":"Levy CE, Lash AT, Janoff HB, Kaplan FS. Conductive hearing loss in individuals with fibrodysplasia ossificans progressiva. Am J Audiol. 1999;8(1):29\u201333.","journal-title":"Am J Audiol"},{"issue":"1","key":"3763_CR22","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1017\/S0022215100068481","volume":"82","author":"H Ludman","year":"1968","unstructured":"Ludman H, Hamilton EB, Eade AW. Deafness in myositis ossificans progressiva. J Laryngol Otol. 1968;82(1):57\u201363.","journal-title":"J Laryngol Otol"},{"issue":"1","key":"3763_CR23","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s12519-019-00302-x","volume":"16","author":"JM Zhang","year":"2020","unstructured":"Zhang JM, Li CF, Ke SY, Piao YR, Han TX, Kuang WY, et al. Analysis of clinical manifestations and treatment in 26 children with fibrodysplasia ossificans progressiva in China. World J Pediatr. 2020;16(1):82\u20138.","journal-title":"World J Pediatr"},{"key":"3763_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115274","volume":"134","author":"RJ Pignolo","year":"2020","unstructured":"Pignolo RJ, Cheung K, Kile S, Fitzpatrick MA, De Cunto C, Al Mukaddam M, et al. Self-reported baseline phenotypes from the International Fibrodysplasia Ossificans Progressiva (FOP) Association Global Registry. Bone. 2020;134:115274.","journal-title":"Bone"},{"issue":"346","key":"3763_CR25","first-page":"104","volume":"346","author":"WG Kussmaul","year":"1998","unstructured":"Kussmaul WG, Esmail AN, Sagar Y, Ross J, Gregory S, Kaplan FS. Pulmonary and cardiac function in advanced fibrodysplasia ossificans progressiva. Clin Orthop Relat Res. 1998;346(346):104\u20139.","journal-title":"Clin Orthop Relat Res"},{"issue":"1","key":"3763_CR26","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s13023-020-01465-x","volume":"15","author":"S Kou","year":"2020","unstructured":"Kou S, De Cunto C, Baujat G, Wentworth KL, Grogan DR, Brown MA, et al. Patients with ACVR1(R206H) mutations have an increased prevalence of cardiac conduction abnormalities on electrocardiogram in a natural history study of fibrodysplasia ossificans progressiva. Orphanet J Rare Dis. 2020;15(1):193.","journal-title":"Orphanet J Rare Dis"},{"key":"3763_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2021.100758","volume":"14","author":"E Botman","year":"2021","unstructured":"Botman E, Smilde BJ, Hoebink M, Treurniet S, Raijmakers P, Kamp O, et al. Deterioration of pulmonary function: an early complication in fibrodysplasia ossificans progressiva. Bone Rep. 2021;14:100758.","journal-title":"Bone Rep"},{"issue":"6","key":"3763_CR28","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1136\/thx.36.6.419","volume":"36","author":"JM Connor","year":"1981","unstructured":"Connor JM, Evans CC, Evans DA. Cardiopulmonary function in fibrodysplasia ossificans progressiva. Thorax. 1981;36(6):419\u201323.","journal-title":"Thorax"},{"issue":"2","key":"3763_CR29","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1213\/ANE.0000000000000021","volume":"118","author":"E Kilmartin","year":"2014","unstructured":"Kilmartin E, Grunwald Z, Kaplan FS, Nussbaum BL. General anesthesia for dental procedures in patients with fibrodysplasia ossificans progressiva: a review of 42 cases in 30 patients. Anesth Analg. 2014;118(2):298\u2013301.","journal-title":"Anesth Analg"},{"issue":"12","key":"3763_CR30","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1007\/s00415-012-6562-y","volume":"259","author":"JA Kitterman","year":"2012","unstructured":"Kitterman JA, Strober JB, Kan L, Rocke DM, Cali A, Peeper J, et al. Neurological symptoms in individuals with fibrodysplasia ossificans progressiva. J Neurol. 2012;259(12):2636\u201343.","journal-title":"J Neurol"},{"issue":"8","key":"3763_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10181","volume":"3","author":"K Peng","year":"2019","unstructured":"Peng K, Cheung K, Lee A, Sieberg C, Borsook D, Upadhyay J. Longitudinal evaluation of pain, flare-up, and emotional health in fibrodysplasia ossificans progressiva: analyses of the International FOP Registry. JBMR Plus. 2019;3(8):e10181.","journal-title":"JBMR Plus"},{"issue":"1","key":"3763_CR32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1258\/om.2011.110042","volume":"5","author":"JA Muglu","year":"2012","unstructured":"Muglu JA, Garg A, Pandiarajan T, Shore EM, Kaplan FS, Uchil D, et al. Pregnancy in fibrodysplasia ossificans progressiva. Obstet Med. 2012;5(1):35\u20138.","journal-title":"Obstet Med"},{"key":"3763_CR33","first-page":"9857766","volume":"2022","author":"AD Forrest","year":"2022","unstructured":"Forrest AD, Vuncannon DM, Ellis JE, Grunwald Z, Kaplan FS. Fibrodysplasia ossificans progressiva and pregnancy: a case series and review of the literature. Case Rep Obstet Gynecol. 2022;2022:9857766.","journal-title":"Case Rep Obstet Gynecol"},{"issue":"12","key":"3763_CR34","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1097\/CORR.0000000000002672","volume":"481","author":"CM Lindborg","year":"2023","unstructured":"Lindborg CM, Al Mukaddam M, Baujat G, Cho T-J, De Cunto CL, Delai PLR, et al. Most fractures treated nonoperatively in individuals with fibrodysplasia ossificans progressiva heal with a paucity of flareups, heterotopic ossification, and loss of mobility. Clin Orthop Relat Res. 2023;481(12):2447\u201358.","journal-title":"Clin Orthop Relat Res"},{"issue":"10","key":"3763_CR35","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.2106\/00004623-199410000-00002","volume":"76","author":"PB Shah","year":"1994","unstructured":"Shah PB, Zasloff MA, Drummond D, Kaplan FS. Spinal deformity in patients who have fibrodysplasia ossificans progressiva. J Bone Jt Surg Am. 1994;76(10):1442\u201350.","journal-title":"J Bone Joint Surg Am"},{"issue":"Suppl. 1","key":"3763_CR36","first-page":"93","volume":"94","author":"RJ Pignolo","year":"2021","unstructured":"Pignolo RJ, Baujat G, Brown MA, De Cunto C, Hsiao EC, Keen R, et al. Abstracts. Hormone Res Paediatr. 2021;94(Suppl. 1):1\u2013445.","journal-title":"Hormone Res Paediatr"},{"issue":"1","key":"3763_CR37","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13023-021-01709-4","volume":"16","author":"K Peng","year":"2021","unstructured":"Peng K, Karunakaran KD, Labadie R, Veliu M, Cheung C, Lee A, et al. Suppressed prefrontal cortex oscillations associate with clinical pain in fibrodysplasia ossificans progressiva. Orphanet J Rare Dis. 2021;16(1):54.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3763_CR38","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13023-022-02246-4","volume":"17","author":"S Kou","year":"2022","unstructured":"Kou S, Kile S, Kambampati SS, Brady EC, Wallace H, De Sousa CM, et al. Social and clinical impact of COVID-19 on patients with fibrodysplasia ossificans progressiva. Orphanet J Rare Dis. 2022;17(1):107.","journal-title":"Orphanet J Rare Dis"},{"issue":"5 Pt 1","key":"3763_CR39","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/S0022-3476(95)70408-6","volume":"126","author":"TF Lanchoney","year":"1995","unstructured":"Lanchoney TF, Cohen RB, Rocke DM, Zasloff MA, Kaplan FS. Permanent heterotopic ossification at the injection site after diphtheria-tetanus-pertussis immunizations in children who have fibrodysplasia ossificans progressiva. J Pediatr. 1995;126(5 Pt 1):762\u20134.","journal-title":"J Pediatr"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03763-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03763-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03763-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T09:36:22Z","timestamp":1748684182000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03763-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,31]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3763"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03763-8","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,31]]},"assertion":[{"value":"4 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SR, AS, SJO (at the time of the study), and CK are employees of and may be stockholders in Regeneron Pharmaceuticals, Inc. HH was a contractor for Regeneron Pharmaceuticals, Inc. at the time the study was conducted.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"262"}}